GSK

(i) Before the CCI and the Competition Appellate Tribunal on the participation in bids to supply meningitis vaccines to the DADG (ii) On securing an unconditional approval from the CCI for its proposed internal restructuring of its consumer health care business through a demerger of GSK CH HoldCo and a series of share exchanges by Pfizer and GSK/GSK affiliates for shares in Haleon